Harm Reduction Therapeutics' New Drug Application for RiVive(TM) Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA

Low-cost, over-the-counter naloxone nasal spray advances to FDA review. Approval would increase access to this lifesaving medicine for the emergency treatment of opioid overdose. PITTSBURGH, Dec. 26, 2022 -- (Healthcare Sales & Marketing Network) -- Ha... Biopharmaceuticals, Drug Delivery, FDA Harm Reduction Therapeutics, RiVive, intranasal, naloxone
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news